

DURECT CORP  
Form 8-K  
October 22, 2004

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of**  
**The Securities Exchange Act of 1934**

**October 22, 2004**

Date of Report (Date of earliest event reported)

**DURECT CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction  
  
of Incorporation)

**000-31615**  
(Commission  
  
File Number)

**94-3297098**  
(IRS Employer  
  
Identification No.)

Edgar Filing: DURECT CORP - Form 8-K

**10240 Bubb Road**

**Cupertino, CA**  
(Address of principal executive offices)

**95014**  
(Zip Code)

Registrant's telephone number, including area code

**(408) 777-1417**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On October 22, 2004, DURECT Corporation, a Delaware corporation (DURECT ), announced the initiation of a Phase I trial for its proprietary transdermal sufentanil patch. This Current Report is filed to disclose nonpublic information required to be disclosed by Regulation FD.

A copy of DURECT's press release announcing the initiation of a Phase I trial for its proprietary transdermal sufentanil patch is attached as Exhibit 99.1 hereto and incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits.**

(c) Exhibits

99.1 Press Release of DURECT Corporation dated October 22, 2004

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DURECT Corporation**

Date: October 22, 2004

By: */s/* JAMES E. BROWN  
**James E. Brown**

**President and Chief Executive Officer**

**DURECT CORPORATION**

**INDEX TO EXHIBITS**

<b><u>Exhibit Number</u></b>	<b><u>Description</u></b>
99.1	Press Release of DURECT Corporation dated October 22, 2004